fludarabine

Org: Celledit, The Third Affiliated Hospital of Southern Medical University, The First Affiliated Hospital of University of Science and Technology of China, The Second Xiangya Hospital of Central South University,

Abstract

A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL).

Org: Dana-Farber Cancer Institute, DFCI/PCC Fellowship Program - Attendings, Massachusetts General Hospital, Kite Pharma, Division of Neuroradiology,

Abstract

Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib/II study.

Org: Autolus Therapeutics, H. Lee Moffitt Cancer Center and Research Institute, The David and Etta Jonas Center for Cellular Therapy, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute,

Abstract

Lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial.

Org: Memorial Sloan Kettering Cancer Center, Royal Marsden NHS Foundation Trust, The Christie NHS Foundation Trust and University of Manchester, University of Pittsburgh Medical Center (UPMC), Duke Cancer Institute,

Abstract

Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A.

Org: Orlando Health Cancer Institute, First Department of Medicine, National and Kapodistrian University of Athens, Cooper University Hospital, Norris Comprehensive Cancer Center,

Clinical trial

Phase 1 Study to Evaluate the Safety and Efficacy of TILs Transduced With IL-7 (ADP-TILIL7) in Patients With Locally Advanced or Metastatic Melanoma

Status: Not yet recruiting, Estimated PCD: 2026-03-01

Abstract

Long term follow-up results of BRL-201 phase I study, a CRISPR-based non-viral PD-1 locus specific integrated anti-CD19 CAR-T cells in treating relapsed or refractory non-Hodgkin's lymphoma.

Org: Brl Medicine Inc., Bone Marrow Transplantation Center,

Abstract

FLAG-IDA + venetoclax in newly diagnosed (ND) or relapsed/refractory (RR) AML.

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Leukemia,

Abstract

A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify).

Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, The Bone Marrow and Transplant Group of Georgia, The Colorado Blood Cancer Institute,

Abstract

Reduced dose fludarabine/cyclophosphamide lymphodepletion for tumor-infiltrating lymphocytes therapy (LN-144, lifileucel) in metastatic melanoma.

Org: University of Kansas Cancer Center, Kansas City, KS,

Abstract

Safety and efficacy of AIC100 chimeric antigen receptor (CAR) T-cell therapy in patients with advanced thyroid cancers: Results from the phase 1 study.

Org: UH Seidman Cancer Center,

Abstract

A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial.

Org: Texas Oncology - Baylor Sammons Cancer Center, New South Wales Health,

Abstract

Dynamics of circulating cytokines and chemokines during and after tumor-infiltrating lymphocyte cell therapy with lifileucel in advanced melanoma patients.

Org: Iovance Biotherapeutics, H. Lee Moffitt Cancer Center and Research Institute, UPMC Hillman Cancer Center, The Royal Marsden Hospital NHS Foundation Trust, Perlmutter Cancer Center, NYU Langone Health,

Abstract

A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases.

Org: Stanford University School of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University,

Abstract

Phase I study of GUCY2C CAR-T therapy IM96 in patients with metastatic colorectal cancer.

Org: Beijing Imunopharm Technology Co., Ltd.,

Abstract

A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced solid tumors.

Org: UofL Health – Brown Cancer Center,

Abstract

The promising feeder-free allogenic NK cell therapy: Clinical outcomes of GIC-102 monotherapy (GIC-102101) and synergistic potential with GI-101 (CD80-IgG4 Fc-IL2v) in advanced solid tumors and hematologic malignancies.

Org: GI Cell, GI Innovation,

Clinical trial

Bispecific NK Engager AFM13 Combined With NK Cells for Patients With Recurrent of Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Status: Active (not recruiting), Estimated PCD: 2025-04-15

Clinical trial

A Study Evaluating Escalating Doses of 211^At-Labeled Anti-CD45 MAb BC8-B10 (211^At-BC8-B10) Followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)

Status: , Estimated PCD: 2023-01-13

Clinical trial

Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients With CD19+ B-Cell Lymphoproliferative Neoplasms

Status: Active (not recruiting), Estimated PCD: 2024-12-30

Abstract

Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation.

Org: City of Hope National Medical Center, CIBMTR (Center for International Blood and Marrow Transplant Research), NMDP, Medical College of Wisconsin, Memorial Sloan Kettering Cancer Center,

Abstract

A phase 2, multicenter study of TILs treatment in advanced tumors with alterations in the SWI/SNF complex: The TILTS study.

Org: Early Drug Development Unit, HM Sanchinarro University Hospital, Institut Catala D' Oncologia, Bellvitge Biomedical Research Institute (IDIBELL), Departamento de Ciencias Médicas Básicas, Universidad San Pablo-CEU, CEU Universities,

Abstract

DUET-01: A first-in-human, phase 1/2 study of BOXR1030 in patients with advanced glypican-3-positive solid tumors.

Org: Froedtert and the Medical College of Wisconsin Workforce Health, Milwaukee, WI, SOTIO Biotech Inc., Boston, MA, SOTIO Biotech a.s., Prague, Czech Republic, SOTIO Biotech AG, Basel, Switzerland, Texas Oncology–Baylor Charles A. Sammons Cancer Center, Dallas, TX,

Abstract

The effects of substituting cladribine for fludarabine on outcomes of a reduced intensity conditioning regimen.

Org: Atilim University, Medicana International Ankara Hospital, Medicana Bursa Hospital,

Abstract

OBX-115, an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma.

Org: Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX, Obsidian Therapeutics, Cambridge, MA,

Abstract

STRIvE-02 Arm C: Phase 1 study of concurrent PD-1 inhibition with B7-H3 CAR T cell immunotherapy for recurrent/refractory pediatric solid tumors.

Org: Seattle Children’s Research Institute, Seattle Childrens Research Institute,

Abstract

A phase 1 dose escalation study of a novel coupled CAR T cell therapy, GCC19CART, for patients with metastatic colorectal cancer.

Org: ICT, Innovative Cellular Therapeutics Co.,

Abstract

The interim analysis of a first-in-human phase 1 trial of ET-901, a CRISPR edited allogeneic immune-cloaked anti-CD19 CAR-T cell therapy in patients with r/r B-NHL.

Org: Department of Bio-therapeutic, The First Medical Center, Chinese PLA General Hospital, Beijing, China, EdiGene,

Abstract

Effect of AVM0703 treatment on the limitations of R-CHOP and survival in a model applicable to ABC subtype DLBCL.

Org: AVM Biotechnology,

Clinical trial

Phase II Study of Evaluating the Efficacy of Total Marrow and Lymphoid Irradiation (TMLI) as the Conditioning Regimen for HLA-Haploidentical Hematopoietic Cell Transplantation in Patients With Myelodysplasia or Acute Leukemia

Status: Recruiting, Estimated PCD: 2025-08-04

Clinical trial

A Pilot Study of Lymphodepletion Plus Adoptive Cell Transfer With TGF-Beta Resistant (DNRII) and NGFR Transduced T-Cells Followed by High Dose Interleukin-2 in Patients With Metastatic Melanoma

Status: Active (not recruiting), Estimated PCD: 2024-06-01

Clinical trial

Phase 1 A/B Study of LY2606368 in Combination With Cytarabine and Fludarabine in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS)

Status: Completed, Estimated PCD: 2022-07-12

Clinical trial

A Phase II Study of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Status: Completed, Estimated PCD: 2017-10-31

Clinical trial

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Status: Not yet recruiting, Estimated PCD: 2027-01-18

Clinical trial

International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

Status: Recruiting, Estimated PCD: 2028-07-14

Clinical trial

A Phase II Trial of Haploidentical Allogeneic Stem Cell Transplantation Utilizing Mobilized Peripheral Blood Stem Cells

Status: Active (not recruiting), Estimated PCD: 2023-08-28

Clinical trial

A Phase 1/2 Single-center Study Evaluating the Safety and Efficacy of TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell (ATHENA-2) Therapy in Adults With Refractory/Relapsed B-cell Lymphoma

Status: Recruiting, Estimated PCD: 2026-04-25

Clinical trial

Phase I Study of Autologous Transgenic T-Cells Expressing High Affinity Mesothelin-Specific T-Cell Receptor (TCR) (FH-TCR Tᴍsʟɴ) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Status: Recruiting, Estimated PCD: 2024-06-30

Clinical trial

A Phase II Study of Thiotepa Added to Fludarabine and Melphalan as the Preparative Regime for Alternative Donor Transplantation

Status: Active (not recruiting), Estimated PCD: 2024-06-09

Clinical trial

A Phase II Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

Status: Recruiting, Estimated PCD: 2025-11-01

Clinical trial

Phase I Study to Assess Feasibility and Safety of Adoptive Transfer of Autologous Tumor-Infiltrating Lymphocytes in Combination With Interleukin-2 Followed by Nivolumab Rescue for Advanced Metastatic Melanoma

Status: Active (not recruiting), Estimated PCD: 2026-06-30

Clinical trial

Status: Active (not recruiting), Estimated PCD: 2024-04-01

Clinical trial

Phase II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Peripheral T Cell Lymphoma

Status: Recruiting, Estimated PCD: 2028-02-23

Clinical trial

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

Status: Not yet recruiting, Estimated PCD: 2030-07-01

Clinical trial

Phase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Status: Recruiting, Estimated PCD: 2027-07-01

Clinical trial

A Phase Ib Study to Evaluate Safety and Persistence of ex Vivo Expanded Universal Donor NK Cells in Combination With IL-2 and TGFbeta Receptor I Inhibitor Vactosertib in Patients With Locally Advanced/Metastatic Colorectal Cancer and Relapsed/Refractory Hematologic Malignancies

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Status: Recruiting, Estimated PCD: 2026-02-01

Clinical trial

Allogeneic Hematopoietic Stem Cell Transplantation of α/β T-Lymphocyte Depleted Graft Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

Status: Active (not recruiting), Estimated PCD: 2025-05-01

Clinical trial

Axicabtagene Ciloleucel in Relapsed or Refractory HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphoma

Status: Not yet recruiting, Estimated PCD: 2026-01-31

Clinical trial

Phase I Study of GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Status: Recruiting, Estimated PCD: 2025-12-01

Clinical trial

Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types

Status: Active (not recruiting), Estimated PCD: 2025-06-30

Clinical trial

IL-1 Receptor Antagonist to Prevent Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome

Status: Recruiting, Estimated PCD: 2024-06-01

Clinical trial

A Phase 1 Single Arm, Open Label Study to Evaluate the Safety of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Status: Active (not recruiting), Estimated PCD: 2024-10-01

Clinical trial

Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia

Status: Completed, Estimated PCD: 2016-01-02

Clinical trial

Study of Administration of T Cells Expressing B7-H3 Specific Chimeric Antigen Receptors and Containing the Inducible Caspase 9 Safety Switch in Subjects With Triple Negative Breast Cancer

Status: Not yet recruiting, Estimated PCD: 2026-05-01

Clinical trial

Phase I Study of the Administration of T Lymphocytes Co-Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin Lymphoma and Cutaneous T-Cell Lymphoma

Status: Recruiting, Estimated PCD: 2026-09-30

Clinical trial

Phase Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Status: Active (not recruiting), Estimated PCD: 2023-10-31

Clinical trial

A Phase I Study of Intensity Modulated Total Marrow Irradiation (IMTMI) in Addition to Fludarabine/Melphalan Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies

Status: Recruiting, Estimated PCD: 2028-12-01

Clinical trial

A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Status: Recruiting, Estimated PCD: 2027-08-31

Clinical trial

First-Line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL) With Mutated IGHV Gene and Non-Del(17p)

Status: Active (not recruiting), Estimated PCD: 2025-03-31

Clinical trial

A Phase I/II Study of HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome Using Nonmyeloablative Conditioning With Campath-1H

Status: Completed, Estimated PCD: 2019-01-24

Clinical trial

Phase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) During Conditioning for HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Myelodysplasia or Acute Leukemia

Status: Active (not recruiting), Estimated PCD: 2024-06-15

Clinical trial

Risk Stratified Treatment for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia: A Phase I/II Non-randomized Study of Trametinib and Azacitidine With or Without Chemotherapy (IND #164058)

Status: Recruiting, Estimated PCD: 2028-12-01

Clinical trial

JAK Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients With Primary and Secondary Myelofibrosis: A Prospective Study

Status: Active (not recruiting), Estimated PCD: 2022-12-28

Clinical trial

Early HLA Matched Sibling Hematopoietic Stem Cell Transplantation for Children With Sickle Cell Disease: A Sickle Transplant Advocacy and Research Alliance (STAR) Trial

Status: Recruiting, Estimated PCD: 2027-01-01

Clinical trial

Lymphodepleting Chemotherapy With Fludarabine and Cyclophosphamide Prior to Infusion of CAR T Cell Therapy in Patients With Moderate-Severe Renal Dysfunction

Status: Not yet recruiting, Estimated PCD: 2025-08-31

Clinical trial

A Phase 1 Study of GRN163L (Imetelstat) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia That is in Second or Greater Relapse or That is Refractory to Relapse Therapy; Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia in First or Greater Relapse or is Refractory to Relapse Therapy

Status: Not yet recruiting, Estimated PCD: 2026-04-01

Clinical trial

Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a CD123-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR for Patients With CD123+ Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

Status: Active (not recruiting), Estimated PCD: 2024-12-15

Clinical trial

Phase I Study of Escalating Doses of 90Y-DOTA-Anti-CD25 Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan, and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Leukemia or Myelodysplastic Syndrome

Status: Recruiting, Estimated PCD: 2024-12-13

Clinical trial

Ma-Spore ALL-Seq 2020: RNA-Seq and IgH/TCR-Seq to Improve Risk Assignment in Childhood, Adolescent and Young Adult Acute Lymphoblastic Leukaemia

Status: Recruiting, Estimated PCD: 2030-03-01

Clinical trial

Phase 1/2 Dose-Escalation and Cohort Study of STEAP1 CART With Enzalutamide in Participants With mCRPC

Status: Not yet recruiting, Estimated PCD: 2027-03-30

Clinical trial

Phase 1 Study of FLAG-Ida With Pivekimab Sunirine (PVEK [IMGN632]) for Adults With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Status: Recruiting, Estimated PCD: 2026-12-31

Clinical trial

A PedAL/EuPAL Phase 1/2 Trial of IMGN632 in Pediatric Patients With Relapsed or Refractory Leukemia

Status: Withdrawn, Estimated PCD: 2023-09-01

Clinical trial

Phase I/II Clinical Trial of HER2 Targeted HypoSti.CAR-T Cells in Treating Patients With HER2 Positive Local Advanced or Metastatic Solid Tumors

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

MT2009-09: Biochemical Correction of Severe Epidermolysis Bullosa by Allogeneic Stem Cell Transplantation and "Off-the-shelf" Mesenchymal Stem Cells

Status: Completed, Estimated PCD: 2021-08-12

Clinical trial

Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Status: Recruiting, Estimated PCD: 2025-08-01

Clinical trial

Administration of Autologous CAR-T Cells Targeting the CD19 Antigen and Containing the Inducible caspase9 Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Status: Recruiting, Estimated PCD: 2026-04-22

Clinical trial

A Pilot Trial Examining Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic Stem Cell Transplant Recipients Using Myeloablative Busulfan and Fludarabine

Status: Completed, Estimated PCD: 2019-06-07

Clinical trial

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

Status: Recruiting, Estimated PCD: 2027-03-31

Clinical trial

PNOC018 A Phase 1 Clinical Trial of Autologous T Cells Expressing a TCR Specific for H3.3K27M With Inhibition of Endogenous TCR (KIND T Cells) in HLA-A*0201-positive Participants With Newly Diagnosed H3.3K27M-positive Diffuse Midline Gliomas

Status: Recruiting, Estimated PCD: 2029-08-31

Clinical trial

A Pilot Phase I Trial of IL-21 Expanded, Off the Shelf, Third-Party Natural Killer (NK) Cells in Combination With Mogamulizumab in Patients With Cutaneous T-Cell Lymphomas or Adult T-Cell Leukemia/Lymphomas

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

Pilot Study of Anakinra to Mitigate CAR-T Toxicity in Subjects With Relapsed or Refractory Large B-Cell Lymphoma

Status: Completed, Estimated PCD: 2024-05-28

Clinical trial

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as an Immunotherapy for Children With Solid Tumors (CARE)

Status: Not yet recruiting, Estimated PCD: 2026-08-01

Clinical trial

A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible

Status: Recruiting, Estimated PCD: 2033-06-01

Clinical trial

Immunotherapy Using Precision T Cells Specific to Personalized Neo-antigen for the Treatment of Advanced Solid Tumor

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

A Phase I Clinical Trial of T Cells Expressing a Novel Fully-human Anti-BCMA CAR for Treating Multiple Myeloma

Status: Active (not recruiting), Estimated PCD: 2023-01-01

Clinical trial

Phase I/Ib Study of TBI-2001 for Patients With Relapsed or Refractory CD19+ B-cell Lymphoma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)

Status: Recruiting, Estimated PCD: 2025-03-30

Clinical trial

Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation

Status: Recruiting, Estimated PCD: 2032-01-24

Clinical trial

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Status: Recruiting, Estimated PCD: 2035-05-01

Clinical trial

Phase I Dose Escalation Trial of CD19 Directed Chimeric Antigen Receptor T Cell Therapy in the Treatment of Relapsed/Refractory B Cell Malignancies

Status: Recruiting, Estimated PCD: 2024-12-15

Clinical trial

Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies and Non-malignant Disorders

Status: Recruiting, Estimated PCD: 2025-12-20

Clinical trial

A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Status: Recruiting, Estimated PCD: 2025-11-11

Clinical trial

A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (ZUMA-25)

Status: Recruiting, Estimated PCD: 2025-03-01

Clinical trial

Phase 1a/1b Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells (MC10029) in Subjects With Relapsed or Refractory BAFFR-Expressing B-Cell Hematologic Malignancies

Status: Recruiting, Estimated PCD: 2040-12-31

Clinical trial

A Phase I Clinical Trial of Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

Status: Active (not recruiting), Estimated PCD: 2024-08-01

Clinical trial

A Phase 2, Open-Label, Multi-Center Study of Innate Cell Engager AFM13 in Combination With Allogeneic Natural Killer Cells (AB-101) in Subjects With Recurrent or Refractory Hodgkin Lymphoma and CD-30 Positive Peripheral T-Cell Lymphoma

Status: Recruiting, Estimated PCD: 2026-04-30

Clinical trial

A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Status: Recruiting, Estimated PCD: 2027-12-01

Clinical trial

A Phase I Study to Evaluate the Safety of Escalating Doses of Lymphodepleting Conditioning Chemotherapy Prior to CD19 Chimeric Antigen Receptor T Cells in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Status: Recruiting, Estimated PCD: 2025-05-15

Clinical trial

A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Status: Recruiting, Estimated PCD: 2025-04-07

Clinical trial

Phase I/II Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

Status: Recruiting, Estimated PCD: 2026-07-01

Clinical trial

A Phase 1/2 Single-center Study Evaluating the Safety and Efficacy of TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell (ATHENA) Therapy in Adults With Refractory/Relapsed B-cell Non-Hodgkin Lymphoma

Status: Recruiting, Estimated PCD: 2025-09-01

Clinical trial

Radiation- and Alkylator-free Hematopoietic Cell Transplantation for Bone Marrow Failure Due to Dyskeratosis Congenita / Telomere Disease

Status: Active (not recruiting), Estimated PCD: 2024-04-01

Clinical trial

A Phase 3 Multicenter, Randomized, Prospective, Open-label Trial of Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab Plus Venetoclax (RVe) Versus Obinutuzumab (GA101) Plus Venetoclax (GVe) Versus Obinutuzumab Plus Ibrutinib Plus Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

Status: Completed, Estimated PCD: 2024-02-29

Clinical trial

Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha/Beta Depletion (A/B TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults With Hematological Malignancies

Status: Recruiting, Estimated PCD: 2027-11-30

Clinical trial

Anti-Viral Central Memory CD8 Veto Cells in Haploidentical Hematopoietic Stem Cell Transplantation

Status: Recruiting, Estimated PCD: 2025-12-01

Clinical trial

Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

Status: Recruiting, Estimated PCD: 2027-10-22

Clinical trial

A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)

Status: Completed, Estimated PCD: 2018-12-31

Clinical trial

Phase 1 Clinical Trial of Autologous GD2 Chimeric Antigen Receptor (CAR) T Cells (GD2CART) for Diffuse Intrinsic Pontine Gliomas (DIPG) and Spinal Diffuse Midline Glioma (DMG)

Status: Recruiting, Estimated PCD: 2028-07-31

Clinical trial

A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Status: Recruiting, Estimated PCD: 2027-06-29

Clinical trial

Allogenic CD19-targeting Chimeric Antigen Receptor γδT Cells Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

Treatment Optimization in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment - a Phase IV-trial With a Phase III-part to Evaluate Safety and Efficacy of Nelarabine in T-ALL Patients

Status: Active (not recruiting), Estimated PCD: 2022-08-01

Clinical trial

A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-shelf, Third-party Natural Killer Cells (KDS-1001) for the Induction of Relapsed/Refractory Acute Myeloid Leukemia

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Status: Recruiting, Estimated PCD: 2026-03-01

Clinical trial

Phase 1 Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors

Status: Recruiting, Estimated PCD: 2024-10-01

Clinical trial

A Phase Ib Clinical Trial to Evaluate the Administration of Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Status: Recruiting, Estimated PCD: 2031-06-15

Clinical trial

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) Added to Fludarabine, Bendamustine and Rituximab and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Status: Completed, Estimated PCD: 2023-06-28

Clinical trial

Once Daily Intravenous Busulfex as Part of Reduced-toxicity Conditioning for Patients With Relapsed/Refractory Hodgkin's and Non-Hodgkin's Lymphomas Undergoing Allogeneic Hematopoietic Progenitor Cell Transplantation - A Multicenter Phase II Study

Status: Completed, Estimated PCD: 2021-09-27

Clinical trial

T-Cell Depleted, Alternative Donor Transplant in Pediatric and Adult Patients With Severe Sickle Cell Disease (SCD) and Other Transfusion-Dependent Anemias

Status: Recruiting, Estimated PCD: 2024-08-01

Clinical trial

A Two Step Approach to Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies

Status: Active (not recruiting), Estimated PCD: 2024-02-13

Clinical trial

Autologous Activated T-Cells Transduced With A 3rd Generation GD-2 Chimeric Antigen Receptor And iCaspase9 Safety Switch Administered To Patients With Relapsed Or Refractory Neuroblastoma (GRAIN)

Status: Active (not recruiting), Estimated PCD: 2015-12-01

Clinical trial

ATTAMAGE-A1.: Phase I/II Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity MAGE-A1-Specific T-Cell Receptor (TCR) Combined With Atezolizumab in Patients With Metastatic MAGE-A1 Expressing Cancer

Status: Terminated, Estimated PCD: 2022-08-04

Clinical trial

CD34 Selected Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning and CD8+ Memory T Cell Infusion For Patients With Myelodysplastic Syndrome, Acute Leukemia, and Chronic Myelogenous Leukemia

Status: , Estimated PCD: 2025-02-01

Clinical trial

Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies

Status: Terminated, Estimated PCD: 2023-10-19

Clinical trial

Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells to Facilitate the Engraftment of a Single CCR5Δ32 Homozygous or Heterozygous Cord Blood Unit in Patients With HIV and Hematological Malignancies

Status: Terminated, Estimated PCD: 2022-11-11

Clinical trial

A Two-Stage Phase 1 Open-Label Study of huJCAR014, CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells Bearing a Human Binding Domain, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Acute Lymphocytic Leukemia

Status: Terminated, Estimated PCD: 2023-03-23

Clinical trial

A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

A Phase I Safety and Feasibility Study of Cellular Immunotherapy for Extensive Stage Small Cell Neuroendocrine Prostate Cancer Using Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptor

Status: Not yet recruiting, Estimated PCD: 2028-03-15

Clinical trial

Vaccination to Enhance the Anti-Tumor Activity of GD2 Chimeric Antigen Receptor-Expressing, VZV-Specific T Cells in Subjects With Advanced Sarcomas and Neuroblastoma (VEGAS)

Status: Active (not recruiting), Estimated PCD: 2019-10-31

Clinical trial

Phase I/Ib Study of Adoptive NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Reactive Against the NY-ESO-1-specific Cord Blood-derived NK Cells (NY-ESO-1 TCR/IL-15 NK) in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Status: Recruiting, Estimated PCD: 2026-11-30

Clinical trial

Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia

Status: Recruiting, Estimated PCD: 2026-08-01

Clinical trial

NK Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies

Status: Completed, Estimated PCD: 2022-05-10

Clinical trial

Phase I/Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults With Recurrent or Refractory B Cell Malignancies

Status: Active (not recruiting), Estimated PCD: 2024-12-30

Clinical trial

A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

Status: , Estimated PCD: 2024-12-01

Clinical trial

Trial of the Efficacy and Safety of High-dose Immunosuppressive Therapy Based on Fludarabine and Cyclophosphamide-containing Conditioning Regimen Followed by Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Sclerosis.

Status: Recruiting, Estimated PCD: 2025-10-01

Clinical trial

Pilot Open-Label Study of Safety and Efficacy of Ruxolitinib Given Peri-Transplant During Reduced Intensity Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients With Myelofibrosis

Status: Completed, Estimated PCD: 2020-04-16

Clinical trial

A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma

Status: Not yet recruiting, Estimated PCD: 2028-07-01

Clinical trial

A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Status: Completed, Estimated PCD: 2021-09-30

Clinical trial

Autologous TRAC Locus-inserted CD19-targeting Synthetic T-cell Receptor Antigen Receptor T (STAR-T) Cells for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Status: Recruiting, Estimated PCD: 2024-12-15

Clinical trial

A Phase 1 Study to Evaluate Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T Cells in Patients With Primary CNS Lymphoma

Status: Recruiting, Estimated PCD: 2026-07-29

Clinical trial

Clinical Trial Evaluating the Safety and Activity of Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

Status: Recruiting, Estimated PCD: 2024-12-01

Clinical trial

Pilot Study of Adoptive Cell Transfer for the Treatment of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes

Status: Terminated, Estimated PCD: 2020-07-01

Clinical trial

Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion Before Tumor-Infiltrating Lymphocyte Therapy With Lifileucel in Metastatic Melanoma

Status: Recruiting, Estimated PCD: 2025-11-27

Clinical trial

Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Status: Recruiting, Estimated PCD: 2025-12-30

Clinical trial

A Phase II Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes

Status: Recruiting, Estimated PCD: 2024-04-24

Clinical trial

A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients With Metastatic Cancer

Status: Recruiting, Estimated PCD: 2027-03-23

Clinical trial

Allogeneic Transplantation Using Venetoclax, Timed Sequential Busulfan,Cladribine, and Fludarabine Conditioning in Patients With AML and MDS

Status: Active (not recruiting), Estimated PCD: 2025-10-31

Clinical trial

Study to Evaluate the Efficacy and Safety of Relmacabtagene Autoleucel (Relma-cel) as First-Line Therapy in Adult Participants With High-Risk Large B-Cell Lymphoma

Status: Recruiting, Estimated PCD: 2024-02-10

Clinical trial

Dose Escalation Study Phase I/II of Umbilical Cord Blood-Derived CAR-Engineered NK Cells in Conjunction With Lymphodepleting Chemotherapy in Patients With Relapsed/Refractory B-Lymphoid Malignancies

Status: Completed, Estimated PCD: 2023-03-06

Clinical trial

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Status: Recruiting, Estimated PCD: 2027-01-01

Clinical trial

A Phase I Study of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells in Combination With JSMD194, a Small Molecule Inhibitor of Gamma Secretase, in Patients With Relapsed or Persistent Multiple Myeloma

Status: Terminated, Estimated PCD: 2022-04-20

Clinical trial

A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML

Status: Recruiting, Estimated PCD: 2027-02-01

Clinical trial

Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies

Status: Active (not recruiting), Estimated PCD: 2024-02-11

Clinical trial

A Prospective Study of Tocilizumab for the Prevention of Graft Failure and Graft-versus-Host Disease in Haplo-Cord Transplantation

Status: Active (not recruiting), Estimated PCD: 2022-09-28

Clinical trial

A Phase I Trial of CD19-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells Genetically Engineered to Secrete Interleukin 12 (IL-12) and With a Truncated Human Epidermal Growth Factor Receptor (EGFRt) in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies

Status: Recruiting, Estimated PCD: 2027-06-15

Clinical trial

Phase I Clinical Trial of Human AntiCD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia)

Status: Recruiting, Estimated PCD: 2024-06-01

Clinical trial

A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)

Status: Active (not recruiting), Estimated PCD: 2024-11-22

Clinical trial

SJCAR19: A Phase I/II Study Evaluating SJCAR19 (CD19-Specific CAR Engineered Autologous T-Cells) in Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19+ Acute Lymphoblastic Leukemia

Status: Active (not recruiting), Estimated PCD: 2023-07-01

Clinical trial

A 2 Step Approach to Haploidentical Transplant Using Radiation-Based Reduced Intensity Conditioning

Status: Recruiting, Estimated PCD: 2024-10-01

Clinical trial

A Phase 2 Study of SNDX-5613 in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia

Status: Recruiting, Estimated PCD: 2027-12-31

Clinical trial

Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) for the Treatment of Hematological Diseases [MT2015-32]

Status: Completed, Estimated PCD: 2023-04-17

Clinical trial

Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Patients With CD30+ Nonseminomatous Germ Cell Tumors (NSGCT)

Status: Recruiting, Estimated PCD: 2026-12-01

Clinical trial

Phase I/II Study of Sorafenib Added to Busulfan and Fludarabine Conditioning Regimen in Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Lymphocytes Transduced by RV-SFG.CD19.CD28.4-1BBzeta Retroviral Vector - a Unicenter Phase I/II Clinical Trial

Status: Recruiting, Estimated PCD: 2024-01-01

Clinical trial

Phase II Trial of Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in High Risk AML Patients Who Are Not Eligible for Allogeneic Stem Cell Transplantation

Status: Completed, Estimated PCD: 2022-08-03

Clinical trial

A Phase I/II Clinical Trial of NK Cells Administration to Prevent Disease Relapse for Patient With High-Risk Myeloid Malignancies Undergoing Haploidentical Stem-Cell Transplantation

Status: Completed, Estimated PCD: 2022-02-28

Clinical trial

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Status: Recruiting, Estimated PCD: 2027-04-27

Clinical trial

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

Status: Not yet recruiting, Estimated PCD: 2027-01-01

Clinical trial

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

Status: Recruiting, Estimated PCD: 2038-04-30

Clinical trial

Phase 1b/2a Trial of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) From an HLA-partially Matched Related or Unrelated Donor After TCRαβ+ T-cell/CD19+ B-cell Depletion for Patients Who Will Receive a Kidney Transplant (KT) From the Same HSCT/KT Donor

Status: Recruiting, Estimated PCD: 2032-10-01

Clinical trial

CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

Status: Active (not recruiting), Estimated PCD: 2024-07-01

Clinical trial

Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)

Status: Active (not recruiting), Estimated PCD: 2027-07-01

Clinical trial

Phase I Study to Evaluate the Safety and Efficacy of NK Cell Therapy in Acute Myeloid Leukemia (AML).

Status: Not yet recruiting, Estimated PCD: 2026-08-31

Clinical trial

A Phase I Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma

Status: Active (not recruiting), Estimated PCD: 2024-12-01

Clinical trial

Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells as Immunotherapy for Patients With Pediatric Solid Tumors

Status: Active (not recruiting), Estimated PCD: 2021-09-27

Clinical trial

Phase 1 Study of Lintivirally Transduced T Cells Engineered to Contain Anti-CD38 Linked to TCRζ and 4-1BB Signaling Domains in Subjects With Acute Myeloid Leukemia and Multiple Myeloma

Status: Recruiting, Estimated PCD: 2041-05-01

Clinical trial

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

Status: Active (not recruiting), Estimated PCD: 2027-04-01

Clinical trial

A Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Lymphodepleting Chemotherapy and Lenalidomide as Immunotherapy in Patients With Hematologic Malignancies

Status: Completed, Estimated PCD: 2019-07-09

Clinical trial

Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders

Status: Withdrawn, Estimated PCD: 2023-09-18

Clinical trial

A Randomised Phase II Study in Metastatic Melanoma to Evaluate the Efficacy of Adoptive Cellular Therapy With Tumour Infiltrating Lymphocytes (TIL) and Assessment of High Versus Low Dose Interleukin-2

Status: Terminated, Estimated PCD: 2015-07-24

Clinical trial

A Phase I Study of Venetoclax to Augment Epigenetic Modification and Chemotherapy in Pediatric and Young Adult Patients With Relapsed and Refractory Acute Myeloid Leukemia

Status: Recruiting, Estimated PCD: 2026-11-01

Clinical trial

Phase I Trial of GFRα4 CAR T Cells in Adult Patients With Recurrent or Metastatic Medullary Thyroid Cancer

Status: Recruiting, Estimated PCD: 2039-06-01

Clinical trial

CAR- PRISM (PRecision Intervention Smoldering Myeloma): A Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in High-Risk Smoldering Myeloma

Status: Recruiting, Estimated PCD: 2026-01-15

Clinical trial

T Cells Expressing a Fully-Human Anti-CD19 Chimeric Antigen Receptor for Treating B-cell Malignancies

Status: Completed, Estimated PCD: 2018-06-12

Clinical trial

A Pilot Study of CD19-Specific Car T Cells as Consolidation for Older Adults With Acute Lymphoblastic Leukemia in First Remission

Status: Recruiting, Estimated PCD: 2026-07-24

Clinical trial

The Safety,Tolerance and Efficacy of Neoantigen Targeting T Cells Suspension for Intravenous Infusion(Neo-T) to Advanced Solid Tumor

Status: Recruiting, Estimated PCD: 2023-09-01

Clinical trial

A Phase II Study Using the Administration of Autologous T-Cells Engineered Using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients With Metastatic Cancer

Status: Withdrawn, Estimated PCD: 2024-03-08

Clinical trial

Phase I Clinical Trial of Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B-Prolymphocytic Leukemia)

Status: Recruiting, Estimated PCD: 2025-04-30

Clinical trial

A Pilot Study of Lymphodepletion Plus Adoptive Cell Transfer With T -Cells Transduced With CXCR2 and NGFR Followed by High Dose Interleukin-2 in Patients With Metastatic Melanoma

Status: Completed, Estimated PCD: 2023-04-21

Clinical trial

Phase Ib Clinical Trial of Autologous Anti-NY-ESO-1 TCR-Engineered T Cells in Patients With Relapsed/Refractory Locally Advanced or Metastatic NY-ESO-1-Expressing Triple Negative Breast Cancer

Status: Not yet recruiting, Estimated PCD: 2026-08-01

Clinical trial

A Phase IB Clinical Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab With or Without Chemotherapy in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Status: Recruiting, Estimated PCD: 2026-05-01

Clinical trial

Phase 1 Trial of Autologous T Cells Engineered to Express NY-ESO-1 TCR and CRISPR Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T Cells)

Status: Terminated, Estimated PCD: 2020-02-29

Clinical trial

CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease

Status: Active (not recruiting), Estimated PCD: 2026-07-01

Clinical trial

Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances

Status: Recruiting, Estimated PCD: 2026-12-30

Clinical trial

Administration of T Cells Expressing B7-H3 Specific Chimeric Antigen Receptors (CAR) and Containing the Inducible Caspase 9 Safety Switch in Subjects With Recurrent Platinum Resistant Epithelial Ovarian Cancer

Status: Not yet recruiting, Estimated PCD: 2026-03-01

Clinical trial

A Phase 1 Study to Evaluate TAG72-Targeting Chimeric Antigen Receptor (CAR) T Cells in Patients With Advanced Epithelial Ovarian Cancer

Status: Recruiting, Estimated PCD: 2026-04-05

Clinical trial

GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor Modified T Cells (GD2CART) for Osteosarcoma or Neuroblastoma to Increase Systemic Tumor Exposure

Status: , Estimated PCD: 2040-12-31

Clinical trial

A Phase Ib Open-Label Study Evaluating the Safety and Efficacy of NKTR-255 in Combination With CD19-Directed CAR-T Cell Therapy in Patients With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

COBALT: Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation

Status: Completed, Estimated PCD: 2020-02-02

Clinical trial

A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed AML

Status: Withdrawn, Estimated PCD: 2026-09-30

Clinical trial

Partially HLA-Mismatched Related Donor Hematopoietic Stem Cell Transplantation Using Killer Immunoglobulin Receptor and Human Leukocyte Antigen Based Donor Selection

Status: Completed, Estimated PCD: 2023-11-20

Clinical trial

Phase II Study of MK-3475 in Conjunction With Lymphodepletion, TIL, and High or Low Dose IL-2 in Patients With Metastatic Melanoma

Status: Completed, Estimated PCD: 2022-10-12

Clinical trial

Umbilical Cord Blood Transplantation From Unrelated Donors

Status: Recruiting, Estimated PCD: 2025-06-01

Clinical trial

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

Status: Recruiting, Estimated PCD: 2024-07-01

Clinical trial

A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched/Haploidentical Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes

Status: Completed, Estimated PCD: 2021-12-01

Clinical trial

An International Randomised Clinical Trial of Therapeutic Interventions to Assess the Effects on Outcome in Adults With Acute Myeloid Leukaemia and High Risk Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation.

Status: Active (not recruiting), Estimated PCD: 2025-03-01

Clinical trial

Prospective, Single-center, Single-arm, Open-label Study of Obinutuzumab, Zanubrutinib and Lenalidomide Sequential CD19/CD22 CAR-T in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Status: , Estimated PCD: 2024-06-30

Clinical trial

A Phase II Study of Dasatinib (Sprycel®) (NSC #732517) as Primary Therapy Followed by Transplantation for Adults >/= 18 Years With Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG

Status: Completed, Estimated PCD: 2017-11-14

Clinical trial

A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Leukemia or Lymphoma

Status: Not yet recruiting, Estimated PCD: 2031-06-01

Clinical trial

A Pilot Study of Daunorubicin-cytarabine Liposome (CPX-351) Plus FLT3-inhibitor (Midostaurin) as Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia Followed by Consolidation With a CD34+-Selected Allograft

Status: Recruiting, Estimated PCD: 2031-08-01

Clinical trial

A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Status: Active (not recruiting), Estimated PCD: 2019-10-02

Clinical trial

Multicenter Trial for Treatment of Acute Lymphocytic Leukemia in Adults (Pilot Study 06/99)

Status: Completed, Estimated PCD: 2003-11-01

Clinical trial

A Single Dose-escalation and Dose-expansion Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Allogeneic CAR-T Targeting CD19 in Patients With Refractory or Relapsed B Cell Lymphoma.

Status: Not yet recruiting, Estimated PCD: 2024-05-01

Clinical trial

Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen

Status: Active (not recruiting), Estimated PCD: 2023-02-22

Clinical trial

Haploidentical Donor Hematopoietic Cell Transplantation for Patients With Severe Aplastic Anemia

Status: Active (not recruiting), Estimated PCD: 2025-07-01

Clinical trial

Safety and Efficacy Study of Novel Mesothelin CAR-T Cell Therapy in Patients With Mesothelin-positive Advanced Refractory Solid Tumors

Status: Withdrawn, Estimated PCD: 2025-04-30

Clinical trial

Safety and Efficacy Study of Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

Status: Withdrawn, Estimated PCD: 2025-12-31

Clinical trial

Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Treosulfan Based Preparative Regimen

Status: Completed, Estimated PCD: 2021-12-14

Clinical trial

T-cell Therapy in Combination With Checkpoint Inhibitors for Patients With Advanced Ovarian-, Fallopian Tube- and Primary Peritoneal Cancer

Status: Completed, Estimated PCD: 2020-06-01

Clinical trial

A Phase I Study of Anti-CD19 CAR T-cell Therapy With Axicabtagene Ciloleucel (Axi-cel) in Patients With Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphoma

Status: Active (not recruiting), Estimated PCD: 2024-06-01

Clinical trial

A Phase I/IIa Multicenter Study Evaluating the Safety and Efficacy of CAR20(NAP)-T in Patients With Relapsed/Refractory B Cell Lymphoma (CARMA-01 Study)

Status: Recruiting, Estimated PCD: 2027-12-30

Clinical trial

A Single-Arm Phase I/II Study Evaluating the Safety and Clinical Efficacy Of the 2-nd Generation CD19 Autologous CAR T Cells on the CliniMACS Prodigy Automated Manufacturing Platform in Treatment of Paediatric And Young Adult Patients With Relapsed/Refractory B-lineage Acute Lymphoblastic Leukemia

Status: Active (not recruiting), Estimated PCD: 2020-10-15

Clinical trial

A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation With Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

Status: Recruiting, Estimated PCD: 2029-12-01

Clinical trial

Pre-Transplant Immunosuppression and Related Haploidentical Hematopoietic Cell Transplantation for Patients With Severe Hemoglobinopathies

Status: Withdrawn, Estimated PCD: 2022-12-05

Clinical trial

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

Status: Recruiting, Estimated PCD: 2023-10-01

Clinical trial

Phase I Clinical Trial of TSA-CTL (Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes) In the Treatment of Advanced Solid Tumors

Status: Completed, Estimated PCD: 2020-09-01

Clinical trial

A Genetic Risk-Stratified, Randomized Phase II Study of Four Fludarabine/Antibody Combinations for Patients With Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia

Status: Completed, Estimated PCD: 2014-12-01

Clinical trial

Phase I Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors in Participants With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

Randomized Phase 2 Study Testing Two Conditioning Regimen With a Single Prophylaxis of Graft-versus-host Disease by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation

Status: Not yet recruiting, Estimated PCD: 2027-09-15

Clinical trial

Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Patients With Hematological Malignancies Using a Treosulfan-Based Preparative Regimen

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells as Immunotherapy for Patients With Hepatocellular Carcinoma

Status: Completed, Estimated PCD: 2021-11-17

Clinical trial

A Phase I/Ib Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias Harboring KMT2A, NPM1, or Nucleoporin Gene Alterations

Status: Not yet recruiting, Estimated PCD: 2026-09-11

Clinical trial

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Status: Recruiting, Estimated PCD: 2026-08-31

Clinical trial

A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to Patients With CD70-Expressing Cancers

Status: Recruiting, Estimated PCD: 2027-01-01

Clinical trial

Phase I/II Trial to Determine the Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Status: Recruiting, Estimated PCD: 2027-06-25

Clinical trial

Phase I Clinical Trial Using an Engineered Peripheral Blood Graft for Haploidentical Transplantation

Status: Completed, Estimated PCD: 2023-02-13

Clinical trial

A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Status: Recruiting, Estimated PCD: 2026-06-11

Clinical trial

Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients With Hematologic Malignancies

Status: Completed, Estimated PCD: 2019-11-05

Clinical trial

A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants With Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy or Systemic Sclerosis

Status: Recruiting, Estimated PCD: 2027-11-15

Clinical trial

Clinical Study of the Efficacy and Safety of XPO-1 Inhibitors in Combination With CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

Status: , Estimated PCD: 2024-02-10

Clinical trial

A Collaboration Phase 2 Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

Status: Recruiting, Estimated PCD: 2025-03-01

Clinical trial

A Single Center, Open Label, Single Arm Exploratory Clinical Study of CD19-Directed Allogeneic Chimeric Antigen Receptor CART-cell Immunotherapy Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Status: Active (not recruiting), Estimated PCD: 2024-10-20

Clinical trial

Allogeneic Stem Cell Transplant to Induce Mixed Donor Chimerism in Patients With Sickle Cell Disease and Thalassemia

Status: Active (not recruiting), Estimated PCD: 2023-12-01

Clinical trial

Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (ADAPT)

Status: Recruiting, Estimated PCD: 2026-09-01

Clinical trial

Phase I/II Study of HLA-Matched Peripheral Blood Mobilized Hematopoietic Progenitor Cell Transplantation Followed by Allogeneic T-cell Infusion as Adoptive Immunotherapy in Patients With Metastatic Melanoma

Status: Terminated

Clinical trial

Hematopoietic Bone Marrow Transplantation for Patients With High-risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined With Immunosuppression Before and After Transplantation

Status: Terminated, Estimated PCD: 2016-10-01

Clinical trial

A Phase II Study Of Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Status: Active (not recruiting), Estimated PCD: 2022-07-18

Clinical trial

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

Status: Not yet recruiting, Estimated PCD: 2028-12-31

Clinical trial

Phase Ib Study to Evaluate Humanized CD19-Specific CAR T Cells Following Lymphodepleting Chemotherapy in Adult Patients With Relapsed/Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia

Status: Recruiting, Estimated PCD: 2025-08-06

Clinical trial

A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE2016, an Allogeneic Anti-EGFR Conjugated Gamma Delta T Cell (gdT) Therapy in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

Status: Not yet recruiting, Estimated PCD: 2026-12-18

Clinical trial

Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

Status: Active (not recruiting), Estimated PCD: 2025-09-01

Clinical trial

A Phase IB Study to Assess the Safety and Efficacy of Neoadjuvant Administration of Autologous Tumor Infiltrating Lymphocytes (LN144/Lifileucel) and Pembrolizumab for Treatment of Patients With Locally Advanced (Stage IIIB-D)/Metastatic (Stage IV) Melanoma

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)

Status: Active (not recruiting), Estimated PCD: 2018-10-24

Clinical trial

Targeted Astatine-211-Labeled BC8-B10 Monoclonal Antibody as Reduced Intensity Conditioning for Nonmalignant Diseases

Status: , Estimated PCD: 2028-01-09

Clinical trial

MT2015-20: Biochemical Correction of Severe Epidermolysis Bullosa by Allogeneic Cell Transplantation and Serial Donor Mesenchymal Cell Infusions

Status: Completed, Estimated PCD: 2022-11-15

Clinical trial

Phase 1 Trial of Ivosidenib and FLAG Chemotherapy in Relapsed/Refractory IDH1+ Acute Myeloid Leukemia (AML)

Status: Recruiting, Estimated PCD: 2026-12-01

Clinical trial

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Status: Active (not recruiting), Estimated PCD: 2030-02-28

Clinical trial

Addition of Inotuzumab Ozogamicin Pre- and Post-Allogeneic Transplantation

Status: Recruiting, Estimated PCD: 2025-03-31

Clinical trial

A Phase I Trial of Lymphodepletion Plus Adoptive Cell Therapy With High-Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma

Status: Active (not recruiting), Estimated PCD: 2023-05-26

Clinical trial

Phase I Study of Bortezomib With or Without Total Marrow Irradiation (TMI) Using Intensity Modulated Radiation Therapy (IMRT) in Combination With Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation in Patients With High Risk Multiple Myeloma

Status: Active (not recruiting), Estimated PCD: 2019-07-20

Clinical trial

Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease

Status: Recruiting, Estimated PCD: 2025-01-01

Clinical trial

A Phase II Randomized Controlled Trial Comparing GVHD-Reduction Strategies for Allogeneic Peripheral Blood Transplantation (PBSCT) for Patients With Acute Leukemia or Myelodysplastic Syndrome: Selective Depletion of CD45RA+ Naïve T Cells (TND) vs. Post-Transplantation Cyclophosphamide (PTCy)

Status: Recruiting, Estimated PCD: 2026-12-31

Clinical trial

A Phase Ib/2 Trial of Fludarabine/Melphalan/Total Body Irradiation With Post Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis in Matched-Related and Matched-Unrelated Allogeneic Hematopoietic Cell Transplantation

Status: Active (not recruiting), Estimated PCD: 2023-08-21

Clinical trial

IIT2017-03-Merin-HaploBFR: Bendamustine, Fludarabine, And Rituximab Conditioning For Haploidentical Stem Cell Transplantation With CD56-Enriched Donor Cell Infusion For Relapsed/Refractory Lymphoma, Multiple Myeloma, and CLL

Status: Active (not recruiting), Estimated PCD: 2021-11-07

Clinical trial

Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)

Status: Completed, Estimated PCD: 2016-01-01

Clinical trial

Autologous Chimeric Antigen Receptor Engineered T Cell Immunotherapy for Desensitization in Patients Awaiting Kidney Transplantation

Status: Recruiting, Estimated PCD: 2028-12-15

Clinical trial

Phase I/II Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

Status: Recruiting, Estimated PCD: 2025-09-30

Clinical trial

Evaluation of Safety and Efficacy of Treosulfan-cytarabine-fludarabine (FLAT) Combination Prior to Autologous Stem Cell Transplant (HSCT) in Elderly Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Status: Completed, Estimated PCD: 2019-12-31

Clinical trial

A Phase I/II Pilot Study of Memory-like NK Cells to Consolidate TCRαβ T Cell Depleted Haploidentical Transplant in High-risk AML

Status: Recruiting, Estimated PCD: 2028-09-15

Clinical trial

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

Status: Recruiting, Estimated PCD: 2026-10-01

Clinical trial

A Phase I Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T- Cells for Treating B-cell Malignancies

Status: Recruiting, Estimated PCD: 2028-12-30

Clinical trial

A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Follicular Lymphoma

Status: Recruiting, Estimated PCD: 2030-10-01

Clinical trial

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

Status: , Estimated PCD: 2026-07-01

Abstract

Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed/refractory adult B-cell acute lymphoblastic leukemia (r/r B-ALL): Top line results of the pivotal FELIX study.

Org: University College London Cancer Institute, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, Manchester Royal Infirmary, Texas Transplant Physician Grp, PLLC,

Abstract

Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM).

Org: University of Chicago, Novartis Institutes for BioMedical Research, Medical College of Wisconsin, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center,

Abstract

Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment of LCAR-B38M CAR-T: At least 5-year follow-up in LEGEND-2.

Org: State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Shanghai Institute of Hematology, Ruijin Hospital Affiliated With Shanghai Jiao Tong University School of Medicine, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA,

Abstract

Five-year follow-up update of defined-composition CD19 CAR T-cell therapy for relapsed/refractory CLL.

Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Seattle Gummy Company, Wave Life Sciences,

Abstract

Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).

Org: Laboratory of Transplantation Immunotherapy, Cellular and Molecular Therapeutics Branch, NHLBI, NIH, Department of Surgery, Loyola University Chicago, Department of Transfusion Medicine, Clinical Center, NIH, Laboratory of Transplantation Immunotherapy, Cellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institute, National Institutes of Health, National Institutes of Health Clinical Center Department of Laboratory Medicine,

Abstract

BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations.

Org: Istanbul Medipol University Medical Faculty, International School of Medicine, Merck & Co., Inc., Rahway, NJ, Maria Sklodowska-Curie National Institute of Oncology,

Abstract

A phase 1 trial of umbilical cord blood–derived tumor-reactive PD-L1+ natural killer cells engineered to express soluble IL-15 (TRACK-NK) in patients with non–small-cell lung cancer (NSCLC) refractory to PD-1/PD-L1 inhibitors.

Org: Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, City of Hope Comprehensive Cancer Center, City of Hope Beckman Research Institute, Cytoimmune Therapeutics,

Abstract

Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL).

Org: H. Lee Moffitt Cancer Center and Research Institute, University of Miami Sylvester Cancer Center, Ronald Reagan UCLA Medical Center, Mayo Clinic Comprehensive Cancer Center, Phoenix, AZ, Colorado Blood Cancer Institute and Sarah Cannon Research Institute,

Abstract

Addition of venetoclax to FLAI induction chemotherapy (VFLAI) improves survival in patients with intermediate and high-risk AML vs FLAI and 3+7: A GIMEMA Italian Cooperative analysis.

Org: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST (IRCCS), Fondazione Gimema, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori “Dino Amadori” (IRST) IRCCS, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, IRCCS AOU San Martino,

Abstract

AB-101, an allogeneic, non–genetically modified, natural killer (NK) cell therapy, evaluated as monotherapy or in combination with rituximab in R/R non-Hodgkin lymphoma.

Org: Fox Chase Cancer Center, O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham School of Medicine, Norton Cancer Institute, Texas Oncology PA, OHSU - Oregon Health and Science University,

Abstract

A pilot study of lymphodepletion intensity for PBMC-derived, neoantigen-specific CD8+ T cells (Neo-Ts) therapy in patients with advanced solid tumors.

Org: Biotherapy Center, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China, BGI-Shen zhen, Shen Zhen, China,

Abstract

Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM).

Org: Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, MD Anderson Cancer Center, Houston, TX, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, Division of Hematologic Malignancies and Cellular Therapeutics (HMCT), University of Kansas Medical Center, Kansas City, KS, Virginia Commonwealth University Massey Cancer Center, Richmond, VA, Levine Cancer Institute, Charlotte, NC, Mayo Clinic Florida, Jacksonville, FL, Mayo Clinic, Phoenix, AZ, Dana-Farber Cancer Institute, Palm Beach, FL, Dana-Farber Cancer Institute, Boston, MA, H. Lee Moffitt Cancer Center, Tampa, FL, City of Hope Comprehensive Cancer Center, Duarte, CA, The University of Utah Huntsman Cancer Institute, Salt Lake City, UT, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, City of Hope Comprehensive Cancer Center, Durante, CA, Mayo Clinic, Rochester, MN, Stanford University School of Medicine, Stanford, CA,

Abstract

Safety and efficacy profile of a very low dose of MC-1-50 for treatment of r/r NHL.

Org: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, China, Chongqing Precision Biotech Co., Ltd., Chongqing, China,

Abstract

Safety and early efficacy results of phase 1 study of affinity tuned and trackable AIC100 CAR T cells in ICAM-1 positive relapsed and/or refractory advanced poorly differentiated and anaplastic thyroid cancers.

Org: AffyImmune Therapeutics, Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine, Durham, NC, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Weill Medical College of Cornell University/NewYork-Presbyterian Hospital, NYU Langone Health, New York, NY,

Abstract

Myeloablative fractionated busulfan-based conditioning regimen in patients with AML and MDS: Results of a randomized clinical trial comparing 2 fractionation schedules.

Org: University of Texas MD Anderson Cancer Center, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Stem Cell Transplantation & Cellular Therapy,

Abstract

TCR-T cells armored with immune checkpoint blockade in EBV-positive nasopharyngeal carcinoma: The first-in-human phase 1/2 trial.

Org: Institute of Cancer, Xinqiao Hospital, Chongqing, China, Guangdong TCRCure Biopharma Technology Co., Ltd, Guangzhou, China, Biomedical Analysis Center, Chongqing, China, TCRCure Biopharma Corp., Los Angeles, CA, Institute of Molecular and Cell biology & Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore,

Abstract

A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE trial).

Org: Sarah Cannon Research Institute/Tennessee Oncology, Department of Hematology, University of California San Francisco, Icahn School of Medicine, Mount Sinai, Onc/Hem Care Inc, Center for Discovery and Innovation, Hackensack Meridian Health,

Abstract

Effect of bispecific B7H3 x CD19 CAR T cells on host CD19 expression and CAR T cell engraftment.

Org: University of Washington and Fred Hutchinson Cancer Research Centre, Seattle Children's Hospital, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, St. Jude Children's Research Hospital,

Abstract

The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma.

Org: Washington University School of Medicine in St Louis, Stanford Cancer Center, Centre Léon Bérard, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,

Abstract

Impact of fludarabine exposure on the depth and duration of lymphopenia and CAR T-cell outcomes.

Org: Pediatric Oncology Branch, Clinical Center National Institutes of Health, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, Nihon Medi-Physics, Pharmacy Department,

Abstract

A study of frontline therapy in adults >80 years with chronic lymphocytic leukemia (CLL).

Org: Mayo Clinic, Division of Clinical Trials and Biostatistics, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Department of Laboratory and Oncology, Mayo Clinic, Rochester, MN, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN,

Abstract

ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL).

Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Dana-Farber Cancer Institute, MD Anderson Cancer Center, University of Lille,

Abstract

Immunomodulatory AVM0703 enhances R-CHOP anti-lymphoma effect with reduced toxicity: Immune-resistant, aggressive A20 lymphoma model.

Org: AVM Biotechnology, Inc., AVM Biotechnology,

Abstract

Immunomodulatory AVM0703 lacks the association between anti-cancer activity and immune-mediated side-effects of the checkpoint Inhibitors.

Org: AVM Biotechnology, AVM Biotechnology, Inc., University of Florida Department of Health Outcomes and Biomedical Informatics,

Abstract

Real-world data on incidence of acute adverse reactions (AARs) reported in clinical practice.

Org: Medical Day Hospital Unit Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Medical Day Hospital Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Pharmacy Unit Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori-University of Milan,

Abstract

IDH inhibitors or chemotherapy in relapsed or refractory IDHmut acute myeloid leukemia.

Org: VCU School of Medicine, VCU Massey Cancer Center, VCU Department of Internal Medicine, VCU Department of Biostatistics,

Abstract

ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma.

Org: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, Dana-Farber Cancer Institute, Boston, MA, USA, Moffitt Cancer Center and Research Institute, Tampa, FL, Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain, University of Lille, Centre Hospitalier Universitaire, Lille, France,

Abstract

The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma.

Org: Memorial Sloan Kettering Cancer Center, Stanford Cancer Center, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Princess Margaret Cancer Centre,

Abstract

Outcomes with bendamustine lymphodepletion prior to brexucabtagene autoleucel for mantle cell lymphoma.

Org: Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA,

Abstract

Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma (AM) in patients with concomitant chronic lymphocytic leukemia (CLL).

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Princess Alexandra Hospital and University of Queensland, Mayo Clinic,

Abstract

FLAG-IDA or venetoclax in previously treated TP53mut acute myeloid leukemia.

Org: VCU Department of Internal Medicine, VCU Massey Cancer Center, VCU School of Medicine, Virginia Commonwealth University School of Medicine, VCU Department of Biostatistics,

Product

Fludarabine

Abstract

Clinical-grade natural killer cells expanded from donor peripheral blood and anti-leukemia effect against myeloid leukemia.

Org: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China,

Clinical trial

Abatacept for Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease: a Sickle Transplant Alliance for Research Trial

Status: Completed, Estimated PCD: 2021-12-30

Abstract

https://www.abstractsonline.com/pp8/#!/10828/presentation/10272

Clinical trial

A Phase 1/2 Trial of ADI-270 (Engineered γδ Chimeric Receptor [CAR] Vδ1 T Cells Targeting CD70) in Adults With Relapsed or Refractory (R/R) Clear Cell Renal Cell Carcinoma (ccRCC)

Status: Not yet recruiting, Estimated PCD: 2025-06-01

Clinical trial

A Phase 1/2 Single-center Study Evaluating the Safety and Efficacy of TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in Adults With Refractory/Relapsed B-cell Acute Lymphoblastic Leukaemia

Status: Recruiting, Estimated PCD: 2026-07-01

Clinical trial

Phase I Safety and Feasibility Study of Autologous CD8+ T-cells Transiently Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen in Patients With Multiple Myeloma

Status: Terminated, Estimated PCD: 2021-04-19

Clinical trial

A Phase 2 Trial to Evaluate the Efficacy and Safety of WZTL-002 in Patients With Relapsed or Refractory Large B-cell Lymphoma (ENABLE-2)

Status: Not yet recruiting, Estimated PCD: 2026-06-30